Drug Profile
Ladiratuzumab vedotin - Merck/Seagen
Alternative Names: MK-6440; SGN-LIV1ALatest Information Update: 15 Dec 2023
Price :
$50
*
At a glance
- Originator Seattle Genetics
- Developer Merck & Co; Quantum Leap Healthcare Collaborative; Seagen
- Class Antineoplastics; Auristatins; Drug conjugates; Immunoconjugates; Monoclonal antibodies
- Mechanism of Action Apoptosis stimulants; Mitosis inhibitors; Tubulin inhibitors; Tubulin polymerisation inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Adenocarcinoma; Breast cancer; Head and neck cancer; Malignant melanoma; Non-small cell lung cancer; Oesophageal cancer; Prostate cancer; Small cell lung cancer
Most Recent Events
- 14 Dec 2023 Seagen has been acquired by Pfizer
- 28 Nov 2023 Seagen terminates a phase II trial in Oesophageal cancer, Malignant melanoma, Non-small cell lung cancer, Small cell lung cancer, Head and neck cancer, Adenocarcinoma and Prostate cancer (Inoperable/Unresectable, Metastatic disease, Late-stage disease, Second-line therapy or greater) in USA, Taiwan, United Kingdom, South Korea, Australia, Italy (IV) due to portfolio prioritization(NCT04032704)
- 04 Feb 2023 Seagen completes a phase-I development in Breast-cancer (Metastatic disease, Combination therapy, Monotherapy, Second-line therapy or greater, Late-stage disease, Inoperable/unresectable) in USA (IV, Infusion) (NCT01969643)